Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
90Y-hLL2 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| multi | EXPERIMENTAL | escalating in increments of 2.5 mCi/m2 |
| Name | Type | Description |
|---|---|---|
| 90Y-hLL2 | BIOLOGICAL | weekly dosing for either 2 or 3 weeks |
Inclusion Criteria: * All patients must have a histologic or cytological diagnosis of B-cell lymphoma, and have failed at least one regimen of standard chemotherapy. All histologic grades of non-Hodgkin's lymphoma (NHL) will be eligible for these studies. * Patients must be \> 18 years of age * Mea...
90Y-hLL2 is an investigational monoclonal antibody being studied for the treatment of non-Hodgkin lymphoma (NHL), including B-cell NHL. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
90Y-hLL2 is being developed by Gilead Sciences, Inc. (NASDAQ: GILD). The drug is an investigational monoclonal antibody in Phase 1 clinical development for the treatment of non-Hodgkin lymphoma.
90Y-hLL2 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. A Phase 1 safety study of 90Y-hLL2 in patients with non-Hodgkin lymphoma has been completed.
90Y-hLL2 has one completed clinical trial, NCT00421395, a Phase 1 safety study in patients with non-Hodgkin lymphoma, including B-cell NHL. The study enrolled 59 participants and was conducted in France and Germany.
90Y-hLL2 is a radiolabeled form of the monoclonal antibody hLL2, where the antibody is conjugated to the radioisotope yttrium-90. The drug is being studied for its potential to deliver radiation directly to cancer cells in non-Hodgkin lymphoma.